First Patient Enrolled in Debiopharm OXTEND-03 Acromegaly Trial
Debiopharm, a privately-owned Swiss biopharmaceutical company focused on oncology and rare diseases, announced that the first patient has been enrolled in its OXTEND-03 Phase III clinical trial. The study...